Form 4: Quest Diagnostics Director Increases Stake via Dividend

Director Wright L. Lassiter III acquired 6 shares of Quest Diagnostics common stock through a dividend reinvestment plan.

Summary

• Director Wright L. Lassiter III acquired 6 shares of Quest Diagnostics (DGX) common stock.
• The transaction occurred on April 20, 2026, at a price of $194.699 per share.
• The acquisition was executed through a dividend reinvestment plan.
• Following this transaction, the director's total beneficial ownership is 9,063 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding an insider's dividend reinvestment.

Positives

• Demonstrates continued alignment of interests between the director and shareholders through increased equity ownership.

Negatives

• None.

Risks

• None.

Future Outlook

Not applicable as this is a routine disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that routine dividend reinvestment by corporate directors is a standard practice that typically signals long-term confidence in the company's dividend policy and financial stability.

Comparison to Industry Standards

• The transaction is consistent with standard corporate governance practices where directors participate in dividend reinvestment programs.

Stakeholder Impact

• Minimal impact on shareholders as the transaction size is negligible.

Key Dates

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Dividend Reinvestment, Director Ownership